|
18 Feb 2019 |
Clinical Data Presented from PIVOT-02 Study of Bempegaldesleukin (NKTR-214) with Nivolumab in Metastatic Urothelial Carcinoma Patients at the 2019 ASCO Genitourinary Cancers Symposium
|
|
14 Feb 2019 |
DiaMedica Therapeutics Doses First Patient in Phase 1b Clinical Study of DM199 in Patients with Chronic Kidney Disease
|
|
13 Feb 2019 |
Clinigen to acquire US rights to Proleukin
|
|
13 Feb 2019 |
BioArctic's Product Candidate SC0806 for Treatment of Patients With Complete Spinal Cord Injury is now in Phase 2
|
|
12 Feb 2019 |
Ascendis Pharma Initiates Global Phase 2 Trial for TransCon PTH in Adult Subjects with Hypoparathyroidism
|
|
07 Feb 2019 |
Medicenna Presents Promising Clinical Data from Phase 2b Recurrent Glioblastoma Trial of MDNA55
|
|
06 Feb 2019 |
Orphan Technologies Announces First Patients Treated in Phase 1/2 Trial of OT-58 in Homocystinuria
|
|
06 Feb 2019 |
BioVie Completes Patient Enrollment for its Phase 2a Clinical Trial of BIV201 in Refractory Ascites
|
|
06 Feb 2019 |
Medicenna Shows Promising Pre-Clinical Results in Solid Tumor Models with its IL-2 Superkine, MDNA109
|
|
03 Feb 2019 |
Evolus Receives FDA Approval for Jeuveau™ prabotulinumtoxinA-xvfs for Injection
|
|
23 Jan 2019 |
Oramed Initiates Phase I Oral GLP-1 Study Under IND
|
|
23 Jan 2019 |
Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome
|
|
19 Jan 2019 |
ERYTECH Presents TRYbeCA-1 Trial-in-Progress Poster at the 2019 ASCO GI Annual Meeting
|
|
17 Jan 2019 |
Ipsen Presents the Results of the First in-Human Study of a Recombinant Fast-Acting Neurotoxin (rBoNT-E) at TOXINS 2019
|
|
12 Jan 2019 |
Ipsen demonstrates leadership position in neurotoxin research with strong presence at TOXINS 2019
|
|
10 Jan 2019 |
Protagonist Therapeutics Initiates Phase 2 Trial of Novel Hepcidin Mimetic PTG-300 for the Treatment of Patients with Beta Thalassemia
|
|
07 Jan 2019 |
Debiopharm Group Regains the Commercial Rights to Trelstar® (Triptorelin pamoate) and Looks for New Partners in North America
|
|
03 Jan 2019 |
First-in-human Study of Precision Immune Stimulant PIN-2 Demonstrated Pharmacologic Activity and Safety in Patients with Advanced Solid Tumors
|
|
27 Dec 2018 |
Spectrum Pharmaceuticals Announces Submission of Biologics License Application to the FDA for ROLONTIS® (eflapegrastim) as a Treatment for Chemotherapy-Induced Neutropenia
|
|
22 Dec 2018 |
FDA approves longer-acting calaspargase pegol-mknl for ALL
|
|
20 Dec 2018 |
AzurRx BioPharma Announces Initiation of Phase II OPTION Clinical Trial of MS1819-SD in Cystic Fibrosis Patients
|
|
20 Dec 2018 |
Amicus Therapeutics Announces First Patient Dosed in Phase 3 PROPEL Pivotal Study of AT-GAA in Patients with Pompe Disease
|
|
20 Dec 2018 |
Carmot Therapeutics Initiates Phase 1 Trial to Treat Type 2 Diabetes
|
|
19 Dec 2018 |
PharmaEssentia and AOP Orphan Receive Positive CHMP Opinion For Besremi™ (Ropeginterferon alfa-2b) For Treatment Of Polycythemia Vera (PV) In EU
|
|
19 Dec 2018 |
Sophiris Bio Provides Updates on Phase 2b Localized Prostate Cancer Trial Dec
|
